Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. - Wikidata - wikimedia - TriplyDB

Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.

Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.

http://www.wikidata.org/entity/Q45911764

about

Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia Fibroblast growth factor 23 Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?Fibroblast Growth Factor-23-A Potential Uremic Toxin Dextran Nanoparticle Synthesis and Properties Fibroblast growth factor (Fgf) 23 gene transcription depends on actin cytoskeleton reorganization.NFκB-sensitive Orai1 expression in the regulation of FGF23 release.Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients.FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts.The use of fibroblast growth factor 23 testing in patients with kidney disease.Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis.Fibroblast growth factor 23 in acute kidney injury.Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection: a case report and review of the literature.Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats Checkpoint kinase Chk2 controls renal Cyp27b1 expression, calcitriol formation, and calcium-phosphate metabolism.Intravenous iron administration and hypophosphatemia in clinical practice.Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure Fibroblast growth factor 23 and acute kidney injury.Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk Effects of Iron on Vitamin D Metabolism: A Systematic Review.Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia.Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients.Serum phosphorus and association with anemia among a large diverse population with and without chronic kidney disease.FGF23 as a calciotropic hormone High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4.Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.Cord Blood Ferritin and Fibroblast Growth Factor-23 Levels in Neonates Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia.Inflammation regulates fibroblast growth factor 23 production.Safety of intravenous iron use in chronic kidney disease.High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.Effect of Mineral and Bone Metabolism on Restless Legs Syndrome in Hemodialysis Patients.Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature.Severe hypophosphataemia after intravenous iron administration

P2860

Q26750413-0A78FF47-E396-4EF2-B17E-0B8085C451B0 Q26829294-0095E372-AB2E-40D2-B03C-B37BD9C7DF8B Q27002431-6E7F2ED8-46DA-49A3-8743-1FE0752F59DF Q28075648-12AAB6A6-88C6-4968-B379-2884E77F5B88 Q28552476-7A99210E-BAC9-49A7-825D-903F784109D8 Q30315564-5146DACC-7692-4B32-B198-51B00A5EC577 Q30315916-72C78E84-0044-4A36-8EFE-676D8C8948A8 Q33607976-CB9484E4-34FA-4183-9261-EE3D41FDB189 Q33643233-6F93DF32-5624-4FFB-B220-CE87720CAEF9 Q33793927-1D904235-8A5F-4D5C-95E5-9844F9CBF31A Q33835743-93F8EFF4-3181-43AC-A114-21FA6F07308E Q34069793-037D548E-BC3C-4111-96C0-0EEA32EAA9DB Q34280125-9E486DCA-8629-4B99-AC2E-D004DB2D07F8 Q34588573-658DE97C-0F5B-4F30-9010-99CDBBF8D213 Q34884492-AC50CD5D-287A-4D2E-9FE7-9340E036C209 Q35067500-C9E8257A-FB86-40B6-95E8-D29C3DDB3528 Q35077013-FCF3564E-9978-4807-953B-8F997C4A0488 Q35335476-2053F8EA-7F56-4443-ACBD-1AFA80663DC6 Q35591336-9365EF4C-D77A-4CD3-B685-94794FCA4E75 Q35665003-581BF4EE-6599-4C15-BF74-C1CF459E79E7 Q35690579-3B6C9F87-6D3F-4D9B-A44C-98B66BFB0FD2 Q36194460-59EFD2C0-2E17-4E44-9EE1-03F12D9F6A37 Q36209885-5B8BCA0A-84CE-4277-A41E-DA58DDDF197F Q36234188-4BDD9609-95C0-4560-A70D-58F714BD3785 Q36371086-766768AD-94EC-4895-B1F2-E1060BD6F78D Q36614486-CE5C9AAA-04AD-4F52-87FD-E215E87DCB18 Q36722347-4353767C-76BA-4363-A9E9-28B12D0B2D72 Q36750178-A06F0202-2453-4637-B87C-3C2EB9241A93 Q36822751-28E0EA56-488B-4A72-9311-685B674E9A08 Q36863458-E8BC664E-8C24-401E-9DA3-1CE1921737EF Q36935548-3E007F33-CC76-4130-9721-5724BD22CB96 Q37171855-27D458E3-94F5-43AC-8A69-AC72E51E628F Q37243107-6C77AE19-CF9D-4FE7-A33B-F51AD44C9776 Q37320585-66FF193F-84E8-4C98-B761-4C842BBA5844 Q37494947-FAAF9DC4-9176-471F-9D30-A5FB1882B19F Q37530199-F84D9518-D87D-4942-BA02-346A5C0982C8 Q37621547-D3DB13AE-7FBA-47BC-B471-5113BEABC64E Q37629734-155699A9-FFE5-421A-8A97-878E4F09C4D5 Q37632216-9A3827A9-D7E5-4FA8-89A5-041D4B0F214A Q37704389-295AC154-7E5E-4E82-B9A9-40BC935004F4

P2860

Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.

http://www.wikidata.org/entity/Q45911764

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Effects of iron deficiency ane ...... hosphate homeostasis in women.

@en

Effects of iron deficiency ane ...... hosphate homeostasis in women.

@nl

type

label

Effects of iron deficiency ane ...... hosphate homeostasis in women.

@en

Effects of iron deficiency ane ...... hosphate homeostasis in women.

@nl

prefLabel

Effects of iron deficiency ane ...... hosphate homeostasis in women.

@en

Effects of iron deficiency ane ...... hosphate homeostasis in women.

@nl

P1433

Q45911764-2B23239E-B2CF-4D3F-B030-74F038FF70AA

P1476

Q45911764-D0FFBEF3-B3F9-4144-A265-70F9DCC01CD5

P2093

Q45911764-967B2B6F-C4F1-453C-BA91-3F05120B2D89

Q45911764-A30777B1-2A82-4C6D-B4DE-F996FE2C82AD

Q45911764-F3E7B020-98CC-46D4-B09B-C036B54E1AD2

P2860

Q45911764-1E75A823-FE6E-4135-A479-B16715065E35

Q45911764-292F0C51-3410-408E-9380-4C363E84502B

Q45911764-32EC517B-0061-4572-8A87-EF05398A1953

Q45911764-481D5690-3859-4016-91C7-5E1225B4837D

Q45911764-4DF49F64-5F3C-4D1E-84A3-DAE30839FA47

Q45911764-651A1013-E41E-4F9D-92D6-A03F96B6D627

Q45911764-72CFC5F3-BA82-4B82-86B3-ABCD2F4491AF

Q45911764-7B668DE9-66FE-4D4A-B36B-BCDDE538FE3C

Q45911764-84CE19C7-DABE-488B-8BF8-3880DC4142C5

Q45911764-8D3A5007-4AE8-4374-8BEE-7FC23239AF86

P304

Q45911764-C2B9846D-FE3C-49FA-97D6-130E309C1508

P31

Q45911764-36367957-79E5-4013-B0F3-D8B65F084A57

P356

Q45911764-7CFA0543-3E22-425D-A6E9-601C354364AF

P433

Q45911764-B3E705DC-DF41-4C19-8479-8E50335ACED2

P478

Q45911764-046E6C8F-CBAA-4944-B336-8CF03B5AC35A

P577

Q45911764-FAA79F3B-9D21-4EEF-9A5B-703F2C68D24C

P698

Q45911764-F7C2EAD3-194B-4167-B898-0E6EBC3DFDEF

P356

P1433

Journal of Bone and Mineral Research

P1476

Effects of iron deficiency ane ...... hosphate homeostasis in women.

@en

P2093

David B Bregman

http://www.w3.org/2001/XMLSchema#string

Myles Wolf

http://www.w3.org/2001/XMLSchema#string

Todd A Koch

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.

Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial.

FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.

FGF-23: More than a regulator of renal phosphate handling?

Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.

P304

1793-1803

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.1923

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23505057

http://www.w3.org/2001/XMLSchema#string